CPI-613: Additional Phase I data

Data from 7 evaluable patients who received >=1 cycle of treatment in an open-label, dose-escalation, U.S. Phase I trial showed that twice-weekly IV CPI-613 for 3 weeks led to complete remission in 1 ...